fully-armed CAR T-cell product candidate — IND submission
2026
The first IND submission for a fully-armed CAR T-cell product candidate with an undisclosed target for solid tumors is expected in 2026.Source filing
LYEL biotech catalysts & pipeline
LYELL IMMUNOPHARMA INC · Data as of 2026-09-08
Upcoming catalysts
undisclosed target for solid tumors — IND submission
in 2026
The first IND for a fully-armed CAR T-cell product candidate with an undisclosed target for solid tumors is expected in 2026.Source filing
LYL273 — Topline data
H2 2026
Additional data from patients treated in the 3L+ setting of the U.S. Phase 1 trial, and an End-of-Phase 1 FDA meeting, are expected in the second half of 2026.Source filing
rondecabtagene autoleucel — Topline data
H2 2026
Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027.Source filing
LYL314 — NDA/BLA submission
2027
Data from this trial is expected to form the basis of a Biologics License Application submission to the FDA in 2027 for patients with R/R LBCL receiving treatment in the 3L+ setting.Source filing
rondecabtagene autoleucel — Topline data
mid-2027
Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027.Source filing
rondecabtagene autoleucel — NDA/BLA submission
H2 2027
Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027.Source filing